English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

I. lNTRODUCTION  156 II. RELEVANT LAW: INCENTIVES TO SETTLE PATENT INFRINGEMENT SUITS BY AGREEMENT  157 A. Patent Law: Conflicting Interests Give Rise to Incentives to Settle  158 B. The Sherman AntitrustAct: Protecting Competition  160 C. The Complete Process: From ANDA to Settlement..  161 D. Today's Pharmaceutical Market: Market Incentives to Settle Patent Infringement Suits  162 Ill. THE HISTORY OF THE DEBATE  164 A. Schering-Plough: Patent Settlement Agreements with Upsher and ESI  165 B. Zeneca: Patent Settlement Agreement with Barr  166 C. Bayer: Patent Settlement Agreement with Barr  167 IV. THE DETAILS OF THE DEBATE  168 A. The Arguments for Settlement: The Courts and the Industry  168 1. The Courts' Reasoning: Consistently Upholding Settlement Agreements  168 2. The Pharmaceutical Industry: Protecting Investments Through Settlement  170 3. The View of the Generic Manufacturers: A Good Business Decision  172 B. The Arguments Against Patent Settlement Agreements: The FTC and the Consumer  173 1. The FTC: Protecting the Consumer  173 2. Consumer Groups and Other Interested Parties  175 V. MAKING THE CALL: THE BEST OPTION FOR CONGRESS  176 A. The Call for Congressional Action  176 B. Congress' Options: Codification, Legislation, and Limitation  177

Closing the Deal: Making the Right Congressional Decision About Patent Settlement Agreements